새로운 연구 프로젝트와 CSO가 학계로 복귀
스킨바이오테라퓨틱스 plc
("스킨바이오테라퓨틱스" 또는 "회사")
SkinBioTherapeutics initiates new Epiderm project in partnership
with the University of Manchester
Chief Scientific Officer, Prof. Cath O'Neill to move to Scientific Adviser role
18 March 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it has initiated a research and development project with the University of Manchester, named the Epiderm project. The Company also announces that Professor Cath O'Neill has confirmed that she intends to stand down as Chief Scientific Officer (CSO) and move to a Scientific Adviser role.
EpiDerm project with University of Manchester
SkinBioTherapeutics has initiated a research and development project with the University of Manchester, named the Epiderm project (Epiderm). The project is in alignment with the Company's MediBiotix? pillar, which targets the use of the SkinBiotix® technology for medical applications and commercialisation.
The project will be run by Professor Andrew McBain and Professor Sheena Cruickshank. Professor Andrew McBain co-created the SkinBiotix® technology and is an expert in the Microbiome. Professor Sheena is a Professor in Biomedical Sciences and Public Engagement at the University of Manchester and is a highly regarded figure in the field immunology.
Epiderm will explore the use of a non-pathogenic ('friendly') skin bacterium with novel features that support barrier function in the skin. These friendly bacterium encourage the skin to heal by promoting the migration of skin cells, which help close up a wound.
By the end of the six month project, the aim will be to develop a technology derived from specific non-pathogenic skin bacterium that promotes wound healing.
The total budget for the project is £100k which will be joint funded by SkinBioTherapeutics and future grant funding.
SkinBioTherapeutics의 CEO인 Stuart Ashman은 다음과 같이 말했습니다. "The new Epiderm project is an exciting early step in furthering our work in the woundcare space and for our MediBiotix pillar. We are very pleased to continue our longstanding relationship with the University of Manchester and work alongside Professor Andrew McBain once again, as well as begin a new working relationship with Professor Sheena Cruickshank. She is highly respected in the field of immunology. We believe that this project has the potential to form the basis of a new technology for future products and out-licensable opportunities."
Prof. Cath O'Neill
Professor Cath O'Neill has confirmed that she intends to stand down as Chief Scientific Officer (CSO) and move to a Scientific Adviser role so that she can return to full time academia, as Professor of Translational Dermatology at the University of Manchester.
Since the Company was founded, Cath has combined her academic and corporate roles. The Directors have been aware of her eventual desire to return to full time academia for some time.
Cath will retain a close connection with the Company, not only as one of its original founders, but in the capacity as a scientific adviser. She will continue to provide support and guidance on areas such as the intellectual property behind her inventions (AxisBiotix, Skinbiotix) and strategic developments in the microbiome arena. She also retains a significant personal shareholding of 2.47%. The Board has commenced the search for a new CSO.
Martin Hunt, Chairman of SkinBioTherapeutics Plc, 말 :
"Cath has played an important role at SkinBioTherapeutics for many years. The Company is based on the SkinBiotix technology that she invented and developed with Professor Andrew McBain, and she oversaw the Company's IPO as CEO and the first two years of the Company's life. She then moved into the CSO role and has applied her expertise and knowledge to how we can adapt and apply the SkinBiotix technology to a whole range of different skin health pillars.
"She has done all this whilst maintaining her role at Manchester University. Cath has long spoken about her wish to return to academia in due course, and so we wish her all the best now that this time has come. However, we are pleased that she will maintain a connection with us, not just as a shareholder, but also in her capacity as Scientific Adviser."
Catherine O'Neill, Chief Scientific Adviser of SkinBioTherapeutics Plc, said:
"I am very proud of moving the SkinBiotix and AxisBiotix technologies from the lab bench into commercial skin health products, and that they are already having a positive impact. As the understanding of the benefits of the microbiome become even more mainstream, and collaborations with companies like Croda come through, I have every confidence, that my original technologies will form the basis of many other products in the skin health market. I wish the team well and look forward to further successes."
-Ends-
이 발표에서 전달된 정보에는 시장 남용 규정(EU) No. 7/596의 2014조 목적을 위한 내부 정보가 포함되어 있습니다.
자세한 내용은 다음으로 문의하십시오.
스킨바이오테라퓨틱스 plc 스튜어트 J. 애쉬먼, CEO 만프리트 란다와, CFO
| 전화 : + 44 (0) 191 495 7325
|
캐번디시 캐피털 마켓 리미티드 (지명 고문 및 Broker) Giles Balleny, Dan Hodkinson(기업 금융) 찰리 콤(브로킹) Dale Bellis, Tamar Cranford-Smith(영업)
| 전화 : + 44 (0) 20 7220 0500
|
인스팅티프 파트너스(금융지주) 멜라니 토인-세웰 / 잭 킨케이드
| 전화 : + 44 (0) 20 7457 2020
|
편집자 주
SkinBioTherapeutics plc 소개
SkinBioTherapeutics는 피부 건강에 중점을 둔 생명 과학 회사입니다. 회사의 독점 플랫폼 기술인 SkinBiotix®는 맨체스터 대학의 중개 피부과 팀이 발견한 내용을 기반으로 합니다.
회사는 다양한 피부 건강 관리 분야를 목표로 삼고 있으며, 그 중 가장 발전된 분야는 장-피부 축을 활용하여 면역 체계를 조절하는 화장품 스킨케어 및 식품 보충제입니다. 각 분야에서 SkinBioTherapeutics는 인간 연구를 통해 자사의 기술을 예시할 계획입니다. 회사의 첫 번째 제품인 AxisBiotix-Ps?는 경증에서 중등도의 건선 증상을 해결하기 위한 식품 보충제입니다.
회사는 2017년 XNUMX월 AIM에 상장되었으며 영국 뉴캐슬에 본사를 두고 있습니다. 자세한 내용은 다음을 방문하십시오. www.skinbiotherapeutics.com 및 www.axisbiotix.com.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.